TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kairos Pharma, Ltd. ( (KAPA) ) has provided an announcement.
On June 10, 2025, Kairos Pharma, Ltd. entered into a one-year services agreement with Barretto Pacific Corporation to enhance its communication and investor relations efforts in the U.S. market, for a fee of $170,000. On the same day, the company held its annual meeting where stockholders elected directors, ratified auditors, approved executive compensation, and authorized the issuance of common stock, reflecting strategic decisions to strengthen its governance and financial operations.
The most recent analyst rating on (KAPA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd. is a company operating in the pharmaceutical industry, focusing on developing and marketing pharmaceutical products. The company is involved in activities that engage with the brokerage and investment community to enhance its market presence.
Average Trading Volume: 658,561
Technical Sentiment Signal: Strong Sell
For an in-depth examination of KAPA stock, go to TipRanks’ Overview page.